SABCS 2020 Wrap-UpGetting Inside Breast Cancer
Sharon Gentry, a Breast Cancer Nurse Navigator in Winston-Salem, NC, discusses the importance of ENHERTU to patients with HER2-positive breast cancer.
Program Director, Academy of Oncology & Patient Navigators (AONN+)
Lewisville, NC
Sharon Gentry, a Breast Cancer Nurse Navigator in Winston-Salem, NC, discusses the importance of ENHERTU to patients with HER2-positive breast cancer.
Recommended For You
Online FirstA Note From Your NavigatorThe US Food and Drug Administration published updates to the
mammography regulations to require mammography facilities to notify
patients about the density of their breasts.
From Your NavigatorSupport ServicesOncology navigator Sharon Gentry, RN, MSN, explains the value of reaching out to your navigator. A large part of the navigator’s job is to answer questions related to patient care, from transportation and insurance coverage options to cultural concerns, and everything in between.
SABCS 2020 Wrap-UpA phase 2 trial of Enhertu (trastuzumab deruxtecan) in patients with HER2-positive metastatic breast cancer show high rates of positive results in patients who have been heavily pretreated. These results are preliminary and encouraging.
Last modified: March 10, 2022
